Ramírez-Soria M P, España-Gregori E, Aviñó-Martínez J, Pastor-Pascual F
Departamento de Optica, Hospital Universitario La Fe, Valencia, España.
Arch Soc Esp Oftalmol. 2008 Nov;83(11):665-8. doi: 10.4321/s0365-66912008001100007.
A 52-year-old woman with advanced colorectal cancer was referred to us for treatment of Cetuximab-related ocular side-effects.
Cetuximab is a monoclonal antibody that specifically blocks epidermal growth factor receptor activity. It has recently been approved to treat some tumors such as metastatic colorectal cancer and some ORL cancers. Tolerance to it seems to be better than that to the classic chemotherapeutic agents. However it has several side-effects. Cetuximab-related eyelid toxicity has been recently described, though the pathogenesis has not yet been clearly established.
一名患有晚期结直肠癌的52岁女性因西妥昔单抗相关的眼部副作用前来我院接受治疗。
西妥昔单抗是一种特异性阻断表皮生长因子受体活性的单克隆抗体。它最近已被批准用于治疗某些肿瘤，如转移性结直肠癌和一些耳鼻喉科癌症。对它的耐受性似乎优于传统化疗药物。然而，它有几种副作用。最近已描述了西妥昔单抗相关的眼睑毒性，但其发病机制尚未明确。
